Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of allergic asthma \>= 1 year duration and a history consistent with Step 2 or 3 clinical features from the Global Initiative for Asthma guidelines.~* Eligible baseline serum immunoglobulin E (IgE) levels value and body-weight combinations~Exclusion Criteria:~* Documented medical history of anaphylaxis~* Lung disease other than mild to moderate allergic asthma such as chronic obstructive pulmonary disease (COPD)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Omalizumab 900 mg
- 2 (Type: EXPERIMENTAL): Omalizumab 1050 mg
- 3 (Type: EXPERIMENTAL): Omalizumab 1200 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).